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Background
Rhabdomyolysis (RM) may result from gene-environment interactions (1). Mutations
in RYR1 lead to various neuromuscular phenotypes including malignant hyperthermia
susceptibility and RM (2, 3). Preventive measures specifically aimed at RYR1-related RM
mainly consist of avoidance of known triggers such as exercising in hot environments and
untreated pyrexia. We report use of oral dantrolene as a prophylactic treatment for RYR1-
related RM in three severely affected patients (patient consent was obtained for case report
publication) (Table 1).
Case Series:
In all patients recurrent RM episodes were characterized by slow evolution of
symptoms and gradually rising serum creatine kinase (CK) levels over several days following
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exposure to triggers, progressing to abrupt onset of severe muscle breakdown frequently
requiring critical care admission. P1, who was asymptomatic in between recurrent episodes of
RM, was prescribed 25mg oral dantrolene to take at the symptom onset in an attempt to stop
progression to a full RM episode. On follow-up assessment twelve months after treatment
initiation, P1 reported occasional dantrolene use to be beneficial, reporting complete
abatement of symptoms within 20-30 minutes when dantrolene was taken early after onset of
severe myalgia or muscle cramps. He recently had an episode of severe leg pain with rise in
CK (4,111 IU/l). At that time he had run out of danrtrolene tablets. Potential triggers were:
stress, increased caffeine intake and working in a hot environment. He was re-started on
dantrolene 25mg three times daily for two weeks; there was no further rise in CK and his
muscle symptoms normalised within a few days. P2 had a history of debilitating daily muscle
cramps and high CK on minimal activity for two years following his first episode of acute
RM induced by cycling in hot weather. Dantrolene 25mg three times daily was prescribed
for two weeks leading to complete resolution of his symptoms; he was able to resume work
and had marked improvement of his general quality of life. He was able to resume symptom-
free exercise by taking a single dose of 25mg dantrolene prior to physical activity, and has
been cycling 45 minutes twice daily (to and from work). Whilst on dantrolene (12 months),
neither P1 nor P2 had an RM episode. P3 (II.2 from Family 7 in (2, 4)) started using
dantrolene after the second episode of RM at age 15 (CK 378,900 IU/l), at a dose of 25mg
two times daily, increasing to four times daily whenever she experiences increased myalgia
or cramps. On this treatment regime, over a 6.5-year-period she has suffered four additional
episodes of RM, but with less markedly elevated CK levels (varying between 38,860IU/l and
9,738IU/l), not requiring further ICU admissions. All patients reported being more confident
to exercise while using dantrolene. None of the patients had dantrolene-related side-effects,
with persistently normal liver function tests.
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Discussion:
Dantrolene is a muscle relaxant that selectively blocks the RyR1 channel, and its
effects on skeletal muscle are mainly related to the inhibition of intracellular calcium release,
which plays an important role in skeletal muscle excitation-contraction coupling. Dantrolene
has been used for the treatment of malignant hyperthermia, neuroleptic malignant syndrome,
spasticity and recently has been reported as a treatment option for chronic muscle pain in a
patient with MH susceptibility due to RYR1 (5). Adverse effects of dantrolene are usually
more prominent with long-term treatment, and generally minor compared to a severe and
potentially life-threatening RM episode.
We described the intermittent or regular use of dantrolene for the prevention of RYR1-
related RM, probably one of the most common forms of genetically determined exertional
myalgia and RM. In the reported cases, the benefits of dantrolene administration by far
outweighed potential associated risks. Limitations of this study are the small sample size
(n=3) and the relatively short follow-up period for P1 and P2 (twelve months) compared to
P3 (6.5 years).
Dantrolene is very commonly administered orally to (often valuable) rhabdomyolysis-
susceptible Thoroughbred racehorses (2 to 3 mg/kg) in training, typically 60-90 minutes prior
to exercise: experimental and anecdotal evidence suggests the drug is highly efficacious (6,
7). Whilst an RYR1-mutation is unlikely on the basis of linkage analysis in this animal model
(8), a calcium-related homeostatic disorder is supported by prior in vitro caffeine-contracture
experiments (9). Dantrolene reduces sarcoplasmic reticulum calcium release, and lowers
resting calcium in cultured equine muscle cells (10), perhaps accounting for its prophylactic
efficacy in vivo (6, 7). Whilst clinically-detectable side effects following its administration to
horses are very rare at recommended doses, higher doses have been associated with short-
lived paresis in some animals (11); sub-clinical biochemical effects on hepatic function have
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not been reported, despite its worldwide use. Exercise-performance is not knowingly
impaired at recommended doses, thereby enabling incremental training programmes to get a
horse to full fitness. Typically, the drug is used in RM-susceptible animals, when training
levels are increasing in intensity or following a period of rest and its use is withdrawn prior to
racing.
This is the first report indicating a role of dantrolene in preventing and/or
ameliorating RYR1-related RM in humans. Considering the economic impact and quality of
life consequences of recurrent RM, we believe that its occasional use to prevent or abort an
attack of RM should be further investigated. Undertaking a randomised controlled trial to
assess risks and benefits of dantrolene in this group of patients in more detail could help to
evaluate the role this drug in preventing RYR1-related RM, and, possibly, other genetically
determined forms of RM, in particular those related to abnormalities of calcium homeostasis,
excitation-contraction coupling and the triad.
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Table 1: RYR1-related rhabdomyolysis in three European patients
Patient 1* Patient 2* Patient 3
Gender / Age of onset (Current Age) Male / 12yrs (18yrs) Male / 37yrs (40yrs) Female / 14yrs (22yrs)
RYR1 variant (heterozygous) c.8054C>T
p.(Ser2685Phe)
c.6838G>A
p.(Val2280Ile)
c.7300G>A
p.(Gly2434Arg)
PolyPhen-2 Prediction (score) Probably Damaging
(0.978)
Possibly Damaging
(0.952)
Probably Damaging
(0.999)
Previously reported as pathogenic Novel Yes Yes
Freq ExAC 0.000008268
Singleton
0.00003366
<1/10000
0.00002479
<1/10000
Number of RM episodes Several Several Several (six documented)
Number of RM episodes whilst on
Dantrolene
None (12 months) None (12 months) 4 (6.5 years) – CK levels
89-97% lower
than before
Triggers for RM High volumes of Coca
Cola or coffee intake,
stress/anxiety, exercise,
hot ambient temperature
Exercise performed in hot
ambient temperature
Strenuous exercise, viral
infection,
stress/anxiety, lack of
sleep
Highest CK / Baseline CK (IU/l) 250,000 / 182 57,000 / 150 378,900 / 164
History of MH None None None
Muscle Biopsy Minicores Not Performed Mild unevenness of
oxidative staining
Liver function tests following
Dantrolene intake
Normal Normal Normal
*: Diagnosed by next generation sequencing; CK: creatine kinase; MH: malignant
hyperthermia
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